Association of Tumor Necrosis Factor-alpha Promoter Region Gene Polymorphism at Positions -308G/A, -857C/T, and -863C/A with Etanercept Response in Iraqi Rheumatoid Arthritis Patients

Overview

Journal Arch Rheumatol

Specialty Rheumatology

Date 2023 Mar 7

PMID 36879565

Authors

Samer Mohammed

Munaf Zalzala

Faiq Gorial

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aims to evaluate the association between polymorphisms in the promoter region of the tumor necrosis factor-alpha (TNF-α) gene at locations -308G/A, -857C/T, and -863C/A with the tendency of being non-responder to etanercept.

Patients And Methods: Between October 2020 and August 2021, a total of 80 patients (10 males, 70 females; mean age: 50 years; range, 30 to 72 years) with rheumatoid arthritis (RA) receiving etanercept for at least six months were included. The patients were divided into two groups responders and non-responders, based on their response after six months of continuous treatment. Following polymerase chain reaction amplification of the extracted deoxyribonucleic acid, sequencing by Sanger method was performed to identify the polymorphism at the TNF-α promoter region.

Results: In the responder group, the GG genotype of (-308G/A) and the AA genotype of (-863C/A) were both significantly present. The CC genotype of (-863C/A) was significantly present in the non-responders group. The CC of (-863C/A) SNP was the only genotype that appeared to increase the likelihood of being resistant to etanercept. The GG genotype of (-308G/A) was negatively correlated with the likelihood of being a non-responder. The (-857CC) and (-863CC) genotypes were significantly more prevalent in the non-responders group.

Conclusion: The presence of the (-863CC) genotype, alone or in combination with (-857CC), is linked to an increased likelihood of becoming a non-responder to etanercept. The GG genotype of -308G/A and the AA genotype of -863C/A significantly increase the likelihood of becoming responder to etanercept.

Citing Articles

Impact of MTHFR gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients.

Mutlak Q, Kasim A Sci Rep. 2024; 14(1):15119.

PMID: 38956106 PMC: 11219777. DOI: 10.1038/s41598-024-65199-7.

Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients - identification of novel single nucleotide polymorphism: Cross-sectional study.

Mutlak Q, Kasim A, Aljanabi A Medicine (Baltimore). 2024; 103(23):e38448.

PMID: 38847705 PMC: 11155610. DOI: 10.1097/MD.0000000000038448.

rs1800629 Polymorphism and Response to Anti- Treatment in Behçet Syndrome: Data from an Italian Cohort Study.

Padula M, Padula A, DAngelo S, Lascaro N, Radice R, Martelli G J Pers Med. 2023; 13(9).

PMID: 37763115 PMC: 10532840. DOI: 10.3390/jpm13091347.

References

Gambhir D, Lawrence A, Aggarwal A, Misra R, Mandal S, Naik S . Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population. Rheumatol Int. 2009; 30(9):1211-7. DOI: 10.1007/s00296-009-1131-0. View

Ma M, Kingsley G, Scott D . A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2009; 49(1):91-8. DOI: 10.1093/rheumatology/kep331. View

Prajapati R, Plant D, Barton A . Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011; 12(11):1571-85. DOI: 10.2217/pgs.11.114. View

Scardapane A, Ferrante R, Nozzi M, Savino A, Antonucci I, Dadorante V . TNF-α gene polymorphisms and juvenile idiopathic arthritis: Influence on disease outcome and therapeutic response. Semin Arthritis Rheum. 2015; 45(1):35-41. DOI: 10.1016/j.semarthrit.2015.02.003. View

Kang C, Lee K, Yoo D, Kang C, Bae S . The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005; 44(4):547-52. DOI: 10.1093/rheumatology/keh550. View

Chen M, Peng D, Zhang Z, Zuo G, Zhao G . Efficacy of etanercept for treating the active rheumatoid arthritis: an updated meta-analysis. Int J Rheum Dis. 2015; 19(11):1132-1142. DOI: 10.1111/1756-185X.12724. View

Swierkot J, Bogunia-Kubik K, Nowak B, Bialowas K, Korman L, Gebura K . Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint Bone Spine. 2014; 82(2):94-9. DOI: 10.1016/j.jbspin.2014.08.006. View

Danila M, Hughes L, Bridges S . Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics. 2008; 9(8):1011-5. PMC: 3746504. DOI: 10.2217/14622416.9.8.1011. View

Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I . Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis. 2003; 62(6):526-9. PMC: 1754569. DOI: 10.1136/ard.62.6.526. View

10.

Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P . A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2007; 67(4):478-84. PMC: 2750008. DOI: 10.1136/ard.2007.074104. View

11.

Udalova I, Richardson A, Denys A, Smith C, ACKERMAN H, Foxwell B . Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol. 2000; 20(24):9113-9. PMC: 102169. DOI: 10.1128/MCB.20.24.9113-9119.2000. View

12.

Wiens A, Venson R, Correr C, Otuki M, Pontarolo R . Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010; 30(4):339-53. DOI: 10.1592/phco.30.4.339. View

13.

You C, Li X, Li Y, Wang L, Li F, Guo X . Association analysis of single nucleotide polymorphisms of proinflammatory cytokine and their receptors genes with rheumatoid arthritis in northwest Chinese Han population. Cytokine. 2012; 61(1):133-8. DOI: 10.1016/j.cyto.2012.09.007. View

14.

Seitz M, Wirthmuller U, Moller B, Villiger P . The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2006; 46(1):93-6. DOI: 10.1093/rheumatology/kel175. View

15.

Pavy S, Toonen E, Miceli-Richard C, Barrera P, van Riel P, Criswell L . Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2009; 69(6):1022-8. DOI: 10.1136/ard.2009.117622. View

16.

Jawaheer D, Li W, Graham R, Chen W, Damle A, Xiao X . Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet. 2002; 71(3):585-94. PMC: 449696. DOI: 10.1086/342407. View

17.

Abbasi M, Mousavi M, Jamalzehi S, Alimohammadi R, Bezvan M, Mohammadi H . Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2018; 234(7):10018-10031. DOI: 10.1002/jcp.27860. View

18.

Zeng Z, Duan Z, Zhang T, Wang S, Li G, Gao J . Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2012; 23(3):489-95. DOI: 10.1007/s10165-012-0699-5. View

19.

Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D . Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 2007; 57(8):1426-30. DOI: 10.1002/art.23092. View

20.

Baseggio L, Bartholin L, Chantome A, Charlot C, Rimokh R, Salles G . Allele-specific binding to the -308 single nucleotide polymorphism site in the tumour necrosis factor-alpha promoter. Eur J Immunogenet. 2004; 31(1):15-9. DOI: 10.1111/j.1365-2370.2004.00440.x. View